Effect of Digital Therapeutics for Cardiac Rehabilitation in Patients With Acute Myocardial Infarction

Inclusion Criteria: * The patient meets the diagnostic criteria for AMI in the "Diagnosis and Treatment Guidelines for Acute ST-Segment Elevation Myocardial Infarction (2019)" and undergoes PCI for the first time; * The age is between 18 and 75 years old; * The left ventricular ejection fraction (LVEF) is 35% - 50%; * The patient has normal cognition and can cooperate with the test; * The patient signs the informed consent and the agreement to participate in this study. Exclusion Criteria: * Symptom-limited cardiopulmonary exercise test (treadmill) contraindications: 1. Uncontrolled acute coronary syndrome; 2. Acute heart failure; 3. Symptomatic severe aortic stenosis, severe aortic coarctation or descending aortic aneurysm; 4. Acute aortic dissection; 5. Acute myocarditis, pericarditis or endocarditis; 6. Symptomatic or hemodynamically unstable severe arrhythmia; 7. Severe bradyarrhythmia; 8. Acute pulmonary embolism and pulmonary infarction; 9. Acute respiratory failure; 10. Uncontrolled asthma; 11. Peripheral oxygen saturation \< 88% at rest or heart rate \> 120 beats/min; s. Uncontrolled hypertension: systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 100 mmHg; t. Recent stroke or transient ischemic attack; u. Intermuscular venous thrombosis of the lower extremities; v. Orthopedic injury that hinders walking; w. Mental abnormality; x. Those who cannot cooperate; * Patients who have not completed revascularization treatment or have planned revascularization within one year; * Pregnant or lactating patients, or those who plan to become pregnant within one year; * Patients who have received mechanical circulatory support treatment (such as intra-aortic balloon counterpulsation, Impella, ECMO, etc.) or tracheal intubation; * Patients with a history of non-ischemic cardiomyopathy such as viral myocarditis or dilated cardiomyopathy, hypertrophic cardiomyopathy, peripartum cardiomyopathy, etc.; * Patients with moderate or severe valvular heart disease or a history of valve replacement; * Severe liver function abnormality (ALT ≥ 3 times the upper limit of the normal range) or renal function abnormality (eGFR \< 60 mL/min/1.73 m2); * Patients with diseases such as malignant tumors and an expected lifespan of less than one year; * Those who cannot use a smartphone for various reasons and are inconvenient to communicate with the management team; * Those who are participating in other clinical trials; * The researcher believes that there are any other clinical conditions that are not suitable for inclusion in this study.